CHAPTER 1 INTRODUCTION
1.1 Report Description
1.2 Key Benefits
1.3 Key Market Segments
1.4 Research Methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO Perspective
2.2 Market Beyond: What to Expect by 2025
2.2.1 Moderate growth scenario
2.2.2 Rapid growth scenario
2.2.3 Diminishing growth scenario
CHAPTER 3 MARKET OVERVIEW
3.1 Market Definition and Scope
3.2 Changing Landscape of HRPC Market
3.3 Non-Metastatic CRPC Market Perspective
3.4 Metastatic CRPC Market Pre-Chemo and Post-Chemo Settings
3.5 Xtandi vs. Zytiga Detailed Market Outlook Study of 11 Different Attributes
3.6 Key Findings
3.6.1 Top impacting factors
3.6.2 Top investment pockets
3.6.3 Top winning strategies
3.7 Competitive Intelligence of companies and their strategies
3.8 Regulations and Reimbursement Scenario
3.9 Porter€™s Five Forces Analysis
3.9.1 High competition and fragmented nature reduces the power of the suppliers
3.9.2 Scattered nature and large number of buyers moderates the power of the buyers
3.9.3 Intense competition among existing rivalry
3.9.4 High initial cost lowers the threat of new entrants
3.9.5 Unavailability of substitutes moderates the threat of substitutes
3.9.6 Imperative deductions about the CRPC market
3.10 Market Opportunity
3.10.1 Lucrative opportunities in emerging markets
3.10.2 Untapped Non-Metastatic CRPC (nmCRPC) market opportunity
3.11 Market Share Analysis, 2014
3.12 Value Chain Analysis (Company and Product Perspective)
3.12.1 Value chain analysis by companies
3.12.1.1 Developer analysis
3.12.1.2 Manufacturer analysis
3.12.1.3 Marketer analysis
3.12.1.4 Distributor analysis
3.12.1.5 Key Takeaways
3.12.2 Value chain analysis by products
3.13 Patent Analysis
3.14 Market Dynamics
3.14.1 Drivers
3.14.1.1 Rising incidence and high mortality of prostate cancer worldwide
3.14.1.2 Limited treatment options and high unmet need for ideal treatment
3.14.1.3 Strong emerging pipeline and in-line extensions (ILE) opted for existing therapies
3.14.1.4 Growing awareness leading to increased diagnosis
3.14.2 Restraints
3.14.2.1 Limited reimbursement and coverage by payers
3.14.2.2 High costs due to combination therapies
3.14.2.3 Limited survival periods
CHAPTER 4 PIPELINE OVERVIEW
4.1 Study Objectives
4.2 Pipeline Description
4.3 Pipeline Analysis
4.3.1 Drugs in pipeline
4.3.2 Trials according to primary completion year
4.3.3 NMEs and ILEs in CRPC
4.3.4 Companies in CRPC
4.3.5 Failure rates in CRPC
4.4 Study Implications
CHAPTER 5 GLOBAL CRPC MARKET BY THERAPY TYPE
5.1 Hormonal Therapy
5.1.1 Historical milestones
5.1.2 Hormonal therapy product-wise market size and forecast
5.1.3 Key market trends
5.1.4 Key growth factors and opportunities
5.1.5 Market size and forecast
5.2 Chemotherapy
5.2.1 Historical milestones
5.2.2 Chemotherapy product-wise market size and forecast
5.2.3 Key market trends
5.2.4 Key growth factors and opportunities
5.2.5 Market size and forecast
5.3 Immunotherapy
5.3.1 Historical milestones
5.3.2 Immunotherapy product-wise market size and forecast
5.3.3 Key market trends
5.3.4 Key growth factors and opportunities
5.3.5 Market size and forecast
5.4 Radiotherapy
5.4.1 Historical milestones
5.4.2 Radiotherapy product-wise market size and forecast
5.4.3 Key market trends
5.4.4 Key growth factors and opportunities
5.4.5 Market size and forecast
CHAPTER 6 GLOBAL CRPC MARKET BY DRUG DELIVERY METHOD
6.1 Oral Route
6.1.1 Key market trends
6.1.2 Key growth factors and opportunities
6.1.3 Market size and forecast
6.2 Injectable route
6.2.1 Key market trends
6.2.2 Key growth factors and opportunities
6.2.3 Market size and forecast
CHAPTER 7 GLOBAL CRPC MARKET BY GEOGRAPHY
7.1 North America
7.1.1 Key market trends
7.1.2 Key growth factors and opportunities
7.1.3 Market size and forecast
7.2 Europe
7.2.1 Key market trends
7.2.2 Key growth factors and opportunities
7.2.3 Market size and forecast
7.3 Asia-Pacific
7.3.1 Key market trends
7.3.2 Key growth factors and opportunities
7.3.3 Market size and forecast
7.4 LAMEA
7.4.1 Key market trends
7.4.2 Key growth factors and opportunities
7.4.3 Market size and forecast
CHAPTER 8 COMPANY PROFILES
8.1 Johnson & Johnson
8.1.1 Company Overview
8.1.2 Johnson & Johnson Snapshot
8.1.3 Operating Business Segment Overview
8.1.4 Financial performance
8.1.5 Strategic moves and developments
8.1.5.1 PRINCIPAL STRATEGIES: PRODUCT LAUNCH
8.1.5.2 SECONDARY STRATEGIES: APPROVALS
8.1.5.3 OTHER STRATEGIES: ACQUISITIONS
8.1.6 SWOT analysis and strategic deductions
8.2 Dendreon Corporation
8.2.1 Company Overview
8.2.2 Dendreon Corporation Snapshot
8.2.3 Operating Business Segment Overview
8.2.4 Financial performance
8.2.5 Strategic moves and developments
8.2.6 SWOT analysis and strategic deductions
8.3 Sanofi
8.3.1 Company Overview
8.3.2 Sanofi Snapshot
8.3.3 Operating Business Segment Overview
8.3.4 Financial performance
8.3.5 Strategic moves and developments
8.3.6 SWOT analysis and strategic deductions
8.4 Bayer
8.4.1 Company Overview
8.4.2 Bayer Snapshot
8.4.3 Operating Business Segment Overview
8.4.4 Financial performance
8.4.5 Strategic moves and developments
8.4.6 SWOT analysis and strategic deductions
8.5 Astellas Pharma Inc.
8.5.1 Company Overview
8.5.2 Astellas Snapshot
8.5.3 Operating Business Segment Overview
8.5.4 Financial performance
8.5.5 Strategic moves and developments
8.5.6 SWOT analysis and strategic deductions